Previous 10 | Next 10 |
On March 18th Acer Therapeutics ( ACER ) announced that the FDA's Office of New Drugs (OND) denied Acer's appeal of the Complete Response Letter ("CRL") received last June in relation to Acer's New Drug Application (NDA) for EDSIVO™ for the treatment of patients with vascular Ehlers-D...
Gainers: USD Partners (NYSE: USDP ) +127% . More news on: USD Partners LP, Guess', Inc., Harvest Capital Credit Corp., Stocks on the move, , Read more ...
Acer Therapeutics (NASDAQ: ACER ) reports that the FDA has denied its appeal of the Complete Response Letter (CRL) it received in June 2019 regarding its marketing application for Edsivo (celiprolol) for the treatment of an inherited collagen disorder called Ehlers-Danlos syndrome. Mor...
Acer Therapeutics (NASDAQ: ACER ): Q4 GAAP EPS of -$0.51 misses by $0.03 . More news on: Acer Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
NEWTON, Mass., March 18, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced t...
OND denies Acer’s appeal but describes possible paths forward for EDSIVO™ ACER-001 bioequivalence trial complete; New Drug Application submission anticipated early 2021 Targeting osanetant Phase 1/2 trial initiation by end 2020 NEWTON, Mass., March 18, 2020 (...
Acer Therapeutics, Inc. (NASDAQ: ACER) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “With yesterday's update that ACER-001 showed bioequivalence to the already approved Buphenyl for treatment of UCDs, ACER now has green lights...
NEWTON, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced s...
Gainers: Brickell Biotech (NASDAQ: BBI ) +80% . More news on: Brickell Biotech, Inc., Stamps.com Inc., Adesto Technologies Corporation, Stocks on the move, , Read more ...
Data by YCharts Acer Therapeutics Inc. ( ACER ) ("Acer" or the "Company") is a pharmaceutical company headquartered in Newton, Massachusetts. The Company's focus is to acquire commercial or near-commercial stage orphan or ultra-orphan drugs to treat rare and ultra-rare diseases with critic...
News, Short Squeeze, Breakout and More Instantly...
Acer Therapeutics Inc. Company Name:
ACER Stock Symbol:
NASDAQ Market:
Acer Therapeutics Inc. Website:
AERWINS Technologies Inc. (AWIN) is expected to report for Q1 2024 Minera IRL Ltd ADR (MRLLY) is expected to report for quarter end 2023-09-30 SmileDirectClub, Inc. - Ordinary Shares - Class A (SDCCQ) is expected to report $-0.1 for Q3 2023 NextPlay Technologies Inc. (NXTP) is expecte...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Acer Therapeutics Inc. (ACER) is expected to report $-0.13 for Q3 2023